-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to ...

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster ...

SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, ...

Rhythm Pharmaceuticals (RYTM) announced the presentation of new, real-world data that showed four pediatric patients with acquired hypothalamic obesity or congenital hypothalamic obesity achieved ...

Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus ...

WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

BOSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...